CB2 and peripheral inflammatory response in stroke

This dataset comprises the findings obtained in the study aimed at delineating the innate immune response in ischemic stroke patients. The attention was focused on CB2 receptors expression on circulating monocyte subtypes as putative therapeutic target in ischemic stroke and potential regulation by miR-655 expression. In particular, we achieved in healthy control subjects and ischemic patients at 24 and 48 hours after stroke the following evaluations:

1) CB2 and miR-655 gene expression in total monocytes were assayed by rt-PCR. All samples were assayed in triplicate and gene expression levels were calculated according to 2−∆∆Ct = 2− (∆Ct gene − ∆Ct housekeeping gene) formula by using Ct (cycle threshold) values.

2) CB2 protein expression in total peripheral blood monocytes (CD14++ and CD16+) expressed as percentage of total acquired events by cytofluorimetric analysis.

3) cytofluorimetric analysis of the three monocyte subtypes (CD14++/CD16- classical, CD14++/CD16+ intermediate and CD14+/CD16+ non-classical) expressed as percentage of total acquired events.

4) correlation between the percentage of CB2/CD16+ events and stroke severity at admission.

The potential beneficial functions of CD16+ intermediate and nonclassical monocytes in stroke and the elevated expression of CB2 receptor in these subsets strongly suggest that CB2 receptor agonists can be exploited for the treatment of ischemic stroke patients.